P R O H O S T   O n l i n e The Newsletter of Biotechnology Insight and Investment
Eye on the News [ Home | Contents | Search | Next | Previous | Up ]

ANOTHER GENOMICS FIRM VICTORY

giantsblackmeatwhitetreat xndx

Date: 12 Dec 2007
Time: 09:33:45

Comments

http://www.giantsblackmeatwhitetreat.com/?wm_login=topis http://www.heelsandhoes.com/?wm_login=topis http://www.hentaiplayground.com/?wm_login=topis http://www.hollywoodmenexposed.com/?wm_login=topis http://www.hornyspanishflies.com/?wm_login=topis http://www.hornyspanishflies.com/tour2/?wm_login=topis http://www.ispycameltoe.com/?wm_login=topis http://www.milfhunter.com/?id=chikenn

Date: 21 Jun 2001
Time: 07:49:34

Comments

In the post-Human Genome Project genomic firms are delivering a lot better than analysts expectations. In today’s news CuraGen (CRGN) and Bayer announced have jointly elected 12 targets for drug screening, with the intent of identifying new therapeutics in the disease areas of obesity and diabetes. These targets represent previously unknown drug targets associated with these diseases. Bayer is applying its small molecule screening technologies and chemistry expertise to identify chemicals that may interact with these targets and potentially be developed into novel treatments for obesity and diabetes. The worldwide annual market for obesity and diabetes therapies is estimated to be $98 billion.

Bayer is pleased with the speed of the discovery and we too.

They are optimistic and anticipate more successes over the coming months. CuraGen id proud of delivering highly refined drug targets that are more relevant to disease than those identified through other, more random approaches to drug discovery. A typical example is a novel gene and protein that CuraGen determined to be mutated in exceptionally thin mice. “If the diminished function of this gene and protein leads to leanness, an inhibitor of this new pathway may prove to be a therapeutic for obesity", the company said.

Bayer and CuraGen will jointly develop a pipeline of small molecule drugs to treat obesity and diabetes. Existing therapies have not successfully addressed the needs of the patients afflicted by these devastating diseases. They will use their respective expertise in genomics and chemistry (chemistry here is very important) to jointly develop and commercialize therapeutics that will effectively treat these patients, ultimately improving their quality of life.

Recently, CuraGen announced that its scientists have discovered a new member of the platelet-derived growth factor (PDGF) family that has been named PDGF-D. This newly discovered protein occurs naturally in the human body and may have broad applications as a therapeutic because of its unique cellular activity and biochemical properties.

In addition, CuraGen scientists are currently evaluating fully human monoclonal antibodies for inhibiting the function of this protein as potential therapeutics to treat cancer, and cardiovascular and kidney diseases.

The genomics firms seem to be erasing many of the problems that analysts tried to assimilate after the declaration of the publishing of the Human Genome. Prohost introduced to its subscribers the prestigious, scientific promising genomics firms long before the publishing of the genomics map. Now we are saying to all the readers of the web, especially those who missed the first opportunity: Do not lose the genomics revolution’s second opportunity, there will be no third one at this price, but there will be a quarter of a century of successes to enjoy.

(Prohost Fax is posted on the web. It is about another promising genomics company.)

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Send mail to CompanyWebmaster with questions or comments about this web site. Copyright © 2001 CompanyLongName